Spike Family
Release time:
2023-06-25
2007 , when my marriage failed, I was like a duckweed without roots on the water. My heart was at a loss. I lost confidence in myself and my goal in life. By chance, with the support and encouragement of my family, I applied to become an employee of Daye Peak Delivery Room. I still clearly remember that it was January 17, 2008, and I officially joined the company. Since then, I have a stable and decent job, and my life has a new beginning.
Within two days of my employment, I was sent to Fuyang Peak to study. Soon approaching the Spring Festival, many provinces in the south of the rare snow disaster. Being thousands of miles away from home in Zhejiang, I felt uneasy and helpless. I could only hide in the dormitory and cry at night. I didn't know how to go home. To my surprise, Fuyang Jianfeng's colleagues bought a train ticket for me early, arranged a special bus, put snow chains on the wheels, and carefully took me to the railway station all the way. Although the way home was full of twists and turns, I finally got home safely. In that unforgettable winter, I first felt the warmth and love of the spike family.
In Daye Peak Delivery Room, I stayed for 16 years. At first, my team colleagues and I often made mistakes. Every time we made mistakes, the leaders always asked me to write a review to find out the reasons. For this reason, I cried and felt emotional. But every time I found out the mistakes and summed up the lessons, I became more careful about my work. Gradually, I mature and steady, in the face of any emergency can calmly deal. I would like to thank my two "old leaders" Yuan Zong and Yang Zong. Although they have been transferred to Huang Ping Jianfeng and assumed more important responsibilities, I will not forget that it is their guidance and encouragement in their work that has made me continue to progress and grow. It is their care and care in life that makes me open my heart and smile again and again. It is their understanding and tolerance for me, that's why I tried to stick to it when I encountered setbacks, until now; it was their brotherly friendship and family-like care that made me understand the truth that work should be rigorous and life should be happy...
I cherish this job at the peak, it is it that makes me find my own value; it is it that makes me become a self-confident and independent woman, independent of anyone; it allows me to take on my responsibilities, raise my daughter and cultivate talents; it allows me to stay with my parents day and night, and I can't take care of my parents without going out to work; it is for my future life. Guaranteed, I can also be an elegant old lady after retirement.......
As a pinnacle man, I am very proud and proud. In 2013, I had the honor to go to Jinhua to participate in the celebration of the 20th anniversary of Jianfeng Group's listing, excited and cheered with many of Jianfeng's brothers and sisters. This year is also the 30th anniversary of the listing of Jianfeng Group. Looking back on the past, we must not forget the hard work of generations of peak people, and we must not forget the peak spirit that has inspired us to carry forward the past and continue to innovate. I believe that the tomorrow of our big family, peak, will be more brilliant and better! (daye peak zhang hanwen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31